Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.77 +1.96%

+$0.19 today

Market cap
$68.98M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.02M

Average 1.40M

ATRA EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Atara Biotherapeutics, Inc.NASDAQ: ATRA

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA turns negative

Q1 FY2026 EBITDA was -$3.29M, compared with $40.82M a year earlier. Trailing-twelve-month EBITDA was -$5.48M.

Context

  • EBITDA amounted to 32.0% of revenue in FY2025, down 26.8 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of -$6.62M (-117.1%) for the fiscal year ending Dec 2026, a slowdown from the +151.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.29M-33.4% QoQ
Last fiscal yearDec 2025
$38.63M+151.0% YoY
LTMMar 2026
-$5.48M+4.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-108.0%-228.5%-120.4 pp
1 year+151.0%-117.1%-268.1 pp
3-year CAGR—-23.8%—
5-year CAGR+7.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
38.63M USD
Year-over-year change
+151.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ATRA compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +4.6% is the 5th highest of 11, against a peer median of -2.7%.
  • EBITDA amounts to 23.7% of revenue for ATRA, versus a peer median of 301.4%.
ATRA Competitors
EBITDA for ATRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$78.84M USD+1391.3%——
CSBRChampions Oncology, Inc.LTM Jan 2026-$948K USD-111.2%+41.5%1.6%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-$5.48M USD+4.6%—23.7%
COYACoya Therapeutics, Inc.LTM Mar 2026-$21.1M USD-18.3%—265.8%
OVIDOvid Therapeutics Inc.LTM Mar 2026-$24M USD+7.8%—337.0%
CLNNClene Inc.LTM Mar 2026-$29.2M USD-21.6%—21792.5%
CNTXContext Therapeutics Inc.LTM Mar 2026-$40.18M USD-45.5%——
IFRXInflaRx N.V.LTM Mar 2026-€42.36M EUR+1.6%—144435.8%
STTKShattuck Labs, Inc.LTM Mar 2026-$46.23M USD+30.8%—4623.1%
MGNXMacroGenics, Inc.LTM Mar 2026-$50.64M USD-7.0%—32.2%
STROSutro Biopharma, Inc.LTM Mar 2026-$106.12M USD+42.0%—106.5%
Peer median (excluding ATRA) —-2.7%+41.5%301.4%

Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.34M63.57M8.57M128.94M120.77M
Cost of Revenue282M269.99M8.89M21.01M21.21M
Gross Profit(261.66M)(206.42M)(313K)107.93M99.56M
Gross Margin-1286.4%-324.7%-3.7%83.7%82.4%
Research & Development282M272.53M224.79M151.48M37.45M
Selling, General & Admin78.8M68.13M50.91M39.89M26.25M
Operating Expenses78.8M74.1M275.69M191.37M63.7M
Depreciation & Amortization9.35M5.65M4.83M5.05M2.12M
EBITDA(330.75M)(222.26M)(266M)(75.75M)38.63M
EBITDA Margin-1626.1%-349.6%-3102.7%-58.7%32.0%
Operating Income(340.46M)(280.51M)(276.01M)(83.44M)35.86M
Operating Margin-1673.9%-441.2%-3219.5%-64.7%29.7%
Interest Income367K3.06M5.43M2.11M683K
Interest Expense0373K5.29M4.62M3.79M
Other Income / Expenses367K52.22M(105K)(1.98M)(3.14M)
Income Before Tax(340.1M)(228.29M)(276.11M)(85.42M)32.72M
Pre-Tax Margin-1672.1%-359.1%-3220.7%-66.2%27.1%
Income Tax Expense46K12K15K(12K)31K
Net Income(340.14M)(228.3M)(276.13M)(85.4M)32.69M
Net Margin-1672.3%-359.1%-3220.9%-66.2%27.1%
EPS (Basic)(90.78)(55.96)(65.18)(11.41)2.61
EPS (Diluted)(90.78)(55.96)(65.18)(11.41)2.57
Weighted Avg Shares3.75M4.08M4.24M7.49M12.54M
Weighted Avg Shares (Diluted)3.75M4.08M4.24M7.49M12.72M

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.